Interferon-β modulates the innate immune response against glioblastoma initiating cells

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Wolpert, Fabian ^a   Happold, Caroline ^a   Reifenberger, Guido ^b,c   Florea, Ana Maria ^b,c   Deenen, René ^b   Roth, Patrick ^a   Neidert, Marian Christoph ^d   Lamszus, Katrin ^e   Westphal, Manfred ^e   Weller, Michael ^a   Eisele, Günter ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; HLA E ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NECTIN 2; TRANSCRIPTOME; CELL ADHESION MOLECULE; HLA ANTIGEN CLASS 1; NECTINS;

ADAPTIVE IMMUNITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER STEM CELL; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GLIOBLASTOMA INITIATING CELL; IMMUNOGENICITY; IMMUNOSTIMULATION; INNATE IMMUNITY; LIGAND BINDING; MICROARRAY ANALYSIS; NATURAL KILLER CELL; RECEPTOR BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; DRUG EFFECTS; GENE; GENETICS; GLIOBLASTOMA; HUMAN; IMMUNOLOGY; TUMOR CELL LINE; UPREGULATION;

CELL ADHESION MOLECULES; CELL LINE, TUMOR; GENES, MHC CLASS I; GLIOBLASTOMA; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNITY, INNATE; INTERFERON-BETA; UP-REGULATION;

EID: 84947769509     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0139603     Document Type: Article

References (46)

1. Johnson DR, Ma DJ, Buckner JC, Hammack JE. Conditional probability of long-term survival in glioblastoma: a population-based analysis. Cancer. 2012; 118(22):5608-13. Epub 2012/05/10. doi: 10.1002/cncr.27590 PMID: 22569786.
2. Preusser M, de Ribaupierre S, Wohrer A, Erridge SC, Hegi M, Weller M, et al. Current concepts and management of glioblastoma. Annals of neurology. 2011; 70(1):9-21. doi: 10.1002/ana.22425 PMID: 21786296.
3. Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. The lancet oncology. 2014; 15(9):e395-e403. doi: 10.1016/S1470-2045(14)70011-7 PMID: 25079102.
4. Mohme M, Neidert MC, Regli L, Weller M, Martin R. Immunological challenges for peptide-based immunotherapy in glioblastoma. Cancer treatment reviews. 2014; 40(2):248-58. Epub 2013/09/26. doi: 10.1016/j.ctrv.2013.08.008 PMID: 24064197.
5. Finocchiaro G, Pellegatta S. Immunotherapy for glioma: getting closer to the clinical arena? Current opinion in neurology. 2011; 24(6):641-7. doi: 10.1097/WCO.0b013e32834cbb17 PMID: 22027543.
6. Finocchiaro G, Pellegatta S. Perspectives for immunotherapy in glioblastoma treatment. Current opinion in oncology. 2014; 26(6):608-14. doi: 10.1097/CCO.0000000000000135 PMID: 25210870.
7. Heimberger AB, Sampson JH. Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro Oncol. 2011; 13(1):3-13. doi: 10.1093/neuonc/noq169 PMID: 21149252; PubMed Central PMCID: PMC3018912.
8. Wolpert F, Tritschler I, Steinle A, Weller M, Eisele G. A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells. Neuro Oncol. 2013. Epub 2013/12/12. doi: 10.1093/neuonc/not232 PMID: 24327582.
9. Friese MA, Platten M, Lutz SZ, Naumann U, Aulwurm S, Bischof F, et al. MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer research. 2003; 63(24):8996-9006. PMID: 14695218.
10. Eisele G, Wischhusen J, Mittelbronn M, Meyermann R, Waldhauer I, Steinle A, et al. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain. 2006; 129(Pt 9):2416-25. PMID: 16891318.
11. Castriconi R, Daga A, Dondero A, Zona G, Poliani PL, Melotti A, et al. NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunol. 2009; 182(6):3530-9. PMID: 19265131. doi: 10.4049/jimmunol.0802845
12. Codo P, Weller M, Meister G, Szabo E, Steinle A, Wolter M, et al. MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape. Oncotarget. 2014; 5(17):7651-62. PMID: 25277195; PubMed Central PMCID: PMC4202151.
13. Wolpert F, Roth P, Lamszus K, Tabatabai G, Weller M, Eisele G. HLA-E contributes to an immuneinhibitory phenotype of glioblastoma stem-like cells. Journal of neuroimmunology. 2012; 250(1-2):27-34. Epub 2012/06/13. doi: 10.1016/j.jneuroim.2012.05.010 PMID: 22688424.
14. Wischhusen J, Friese MA, Mittelbronn M, Meyermann R, Weller M. HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo. Journal of neuropathology and experimental neurology. 2005; 64(6):523-8. PMID: 15977644.
15. Wiendl H, Mitsdoerffer M, Hofmeister V, Wischhusen J, Bornemann A, Meyermann R, et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol. 2002; 168(9):4772-80. Epub 2002/04/24. PMID: 11971028.
16. Wang BX, Rahbar R, Fish EN. Interferon: current status and future prospects in cancer therapy. Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research. 2011; 31(7):545-52. Epub 2011/02/18. doi: 10.1089/jir.2010.0158 PMID: 21323567.
17. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994; 264(5164):1415-21. Epub 1994/06/03. PMID: 8197455.
18. Sin WX, Li P, Yeong JP, Chin KC. Activation and regulation of interferon-beta in immune responses. Immunologic research. 2012; 53(1-3):25-40. Epub 2012/03/14. doi: 10.1007/s12026-012-8293-7 PMID: 22411096.
19. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annual review of biochemistry. 1998; 67:227-64. Epub 1998/10/06. doi: 10.1146/annurev.biochem.67.1.227 PMID: 9759489.
20. Bai CZ, Choi S, Nam K, An S, Park JS. Arginine modified PAMAM dendrimer for interferon beta gene delivery to malignant glioma. International journal of pharmaceutics. 2013; 445(1-2):79-87. Epub 2013/02/07. doi: 10.1016/j.ijpharm.2013.01.057 PMID: 23384727.
21. Natsume A, Ishii D, Wakabayashi T, Tsuno T, Hatano H, Mizuno M, et al. IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer research. 2005; 65(17):7573-9. Epub 2005/09/06. PMID: 16140920.
22. Natsume A, Wakabayashi T, Ishii D, Maruta H, Fujii M, Shimato S, et al. A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation. Cancer chemotherapy and pharmacology. 2008; 61(4):653-9. Epub 2007/06/15. doi: 10.1007/s00280-007-0520-x PMID: 17564708.
23. Motomura K, Natsume A, Kishida Y, Higashi H, Kondo Y, Nakasu Y, et al. Benefits of interferon-beta and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study. Cancer. 2011; 117(8):1721-30. Epub 2011/04/08. doi: 10.1002/cncr.25637 PMID: 21472719.
24. Williams RF, Sims TL, Tracey L, Myers AL, Ng CY, Poppleton H, et al. Maturation of tumor vasculature by interferon-beta disrupts the vascular niche of glioma stem cells. Anticancer Res. 2010; 30(9):3301-8. Epub 2010/10/15. PMID: 20944101.
25. Li Y, Zhu H, Zeng X, Fan J, Qian X, Wang S, et al. Suppression of autophagy enhanced growth inhibition and apoptosis of interferon-beta in human glioma cells. Molecular neurobiology. 2013; 47(3):1000-10. Epub 2013/01/19. doi: 10.1007/s12035-013-8403-0 PMID: 23329343.
26. Guo Y, Wang G, Gao WW, Cheng SW, Wang R, Ju SM, et al. Induction of apoptosis in glioma cells and upregulation of Fas expression using the human interferon-beta gene. Asian Pacific journal of cancer prevention: APJCP. 2012; 13(6):2837-40. Epub 2012/09/04. PMID: 22938469.
27. Happold C, Roth P, Silginer M, Florea AM, Lamszus K, Frei K, et al. Interferon-beta induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells. Mol Cancer Ther. 2014. Epub 2014/02/15. doi: 10.1158/1535-7163.MCT-13-0772 PMID: 24526161.
28. Yang X, Zhang X, Fu ML, Weichselbaum RR, Gajewski TF, Guo Y, et al. Targeting the tumor microenvironment with Interferon-beta bridges innate and adaptive immune responses. Cancer cell. 2014; 25 (1):37-48. Epub 2014/01/18. doi: 10.1016/j.ccr.2013.12.004 PMID: 24434209.
29. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004; 432(7015):396-401. PMID: 15549107.
30. Tabatabai G, Weller M. Glioblastoma stem cells. Cell and tissue research. 2011; 343(3):459-65. PMID: 21253762. doi: 10.1007/s00441-010-1123-0
31. Gunther HS, Schmidt NO, Phillips HS, Kemming D, Kharbanda S, Soriano R, et al. Glioblastomaderived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene. 2008; 27(20):2897-909. Epub 2007/11/27. doi: 10.1038/sj.onc.1210949 PMID: 18037961.
32. Van Meir E, Sawamura Y, Diserens AC, Hamou MF, de Tribolet N. Human glioblastoma cells release interleukin 6 in vivo and in vitro. Cancer research. 1990; 50(20):6683-8. PMID: 2208133.
33. Friese MA, Steinle A, Weller M. The innate immune response in the central nervous system and its role in glioma immune surveillance. Onkologie. 2004; 27(5):487-91. Epub 2004/12/09. 80371 [pii] doi: 10.1159/000080371 PMID: 15585981.
34. Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R, Ritz J. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Experimental hematology. 1996; 24(3):406-15. Epub 1996/02/01. PMID: 8599969.
35. Wolpert F, Tritschler I, Steinle A, Weller M, Eisele G. A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells. Neuro Oncol. 2014; 16(3):382-91. Epub 2013/12/12. doi: 10.1093/neuonc/not232 PMID: 24327582; PubMed Central PMCID: PMC3922520.
36. Lee-MacAry AE, Ross EL, Davies D, Laylor R, Honeychurch J, Glennie MJ, et al. Development of a novel flow cytometric cell-mediated cytotoxicity assay using the fluorophores PKH-26 and TO-PRO-3 iodide. J Immunol Methods. 2001; 252(1-2):83-92. PMID: 11334968.
37. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic acids research. 2011; 39(Database issue):D561-8. Epub 2010/11/04. doi: 10.1093/nar/gkq973 PMID: 21045058; PubMed Central PMCID: PMC3013807.
38. Balakrishnan R, Harris MA, Huntley R, Van Auken K, Cherry JM. A guide to best practices for Gene Ontology (GO) manual annotation. Database: the journal of biological databases and curation. 2013; 2013:bat054. Epub 2013/07/12. doi: 10.1093/database/bat054 PMID: 23842463; PubMed Central PMCID: PMC3706743.
39. Watanabe T, Katayama Y, Yoshino A, Fukaya C, Yamamoto T. Human interferon beta, nimustine hydrochloride, and radiation therapy in the treatment of newly diagnosed malignant astrocytomas. Journal of neuro-oncology. 2005; 72(1):57-62. Epub 2005/04/02. doi: 10.1007/s11060-004-2160-x PMID: 15803376.
40. Huang H, Ito K, Dangond F, Dhib-Jalbut S. Effect of interferon beta-1a on B7.1 and B7.2 B-cell expression and its impact on T-cell proliferation. Journal of neuroimmunology. 2013; 258(1-2):27-31. Epub 2013/03/16. doi: 10.1016/j.jneuroim.2013.02.010 PMID: 23489746.
41. Bauvois B, Nguyen J, Tang R, Billard C, Kolb JP. Types I and II interferons upregulate the costimulatory CD80 molecule in monocytes via interferon regulatory factor-1. Biochemical pharmacology. 2009; 78 (5):514-22. Epub 2009/05/13. doi: 10.1016/j.bcp.2009.05.005 PMID: 19433065.
42. Stegmann KA, Bjorkstrom NK, Ciesek S, Lunemann S, Jaroszewicz J, Wiegand J, et al. Interferon alpha-stimulated natural killer cells from patients with acute hepatitis C virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1. The Journal of infectious diseases. 2012; 205(9):1351-62. Epub 2012/03/30. doi: 10.1093/infdis/jis210 PMID: 22457290; PubMed Central PMCID: PMC3690562.
43. Odaka M, Sterman DH, Wiewrodt R, Zhang Y, Kiefer M, Amin KM, et al. Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity. Cancer research. 2001; 61(16):6201-12. Epub 2001/08/17. PMID: 11507073.
44. Nakajima H, Oka Y, Tsuboi A, Tatsumi N, Yamamoto Y, Fujiki F, et al. Enhanced tumor immunity of WT1 peptide vaccination by interferon-beta administration. Vaccine. 2012; 30(4):722-9. Epub 2011/12/03. doi: 10.1016/j.vaccine.2011.11.074 PMID: 22133512.
45. Mizuno M, Yoshida J. Effect of human interferon beta gene transfer upon human glioma, transplanted into nude mouse brain, involves induced natural killer cells. Cancer Immunol Immunother. 1998; 47 (4):227-32. Epub 1999/01/06. PMID: 9875676.
46. Nakahara N, Pollack IF, Storkus WJ, Wakabayashi T, Yoshida J, Okada H. Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells. Cancer gene therapy. 2003; 10(7):549-58. Epub 2003/07/02. doi: 10.1038/sj.cgt.7700598 PMID: 12833135.